OBJECTIVE: Acute respiratory distress syndrome (ARDS) in young infants is linked with a pulmonary inflammatory response part of which are increased interleukin-8 (IL-8) levels and migration of polymorphonuclear leukocytes (PMNL) into lung tissue. A topical application of an antibody against IL-8 might therefore decrease PMNL migration and improve lung function. DESIGN: Randomized, controlled, prospective animal study. SETTING: Research laboratory of a university children's hospital. SUBJECTS AND INTERVENTIONS: Anesthetized, mechanically ventilated newborn piglets (n=22) underwent repeated airway lavage to remove surfactant and to induce lung inflammation. Piglets then received either surfactant alone (S, n=8), or a topical antibody against IL-8 admixed to surfactant (S+IL-8, n=8), or an air bolus injection (control, n=6). MEASUREMENTS AND RESULTS: After 6 h of mechanical ventilation following intervention, oxygenation [S 169+/-51 (SD) vs S+IL-8 139+/-61 mmHg] and lung function (compliance: S 1.3+/-0.4 vs S+IL-8 0.9+/-0.4 ml/cmH(2)O/kg; extra-vascular lung-water: S 27+/-9 vs S+IL-8 52+/-28 ml/kg) were worse in the S+IL-8 group because reactive IL-8 production [S 810 (median, range 447-2323] vs S+IL-8 3485 (628-16180) pg/ml; P<0.05) with facilitated migration of PMNL into lung tissue occurred. Moreover, antibody application caused augmented chemotactic potency of IL-8 [linear regression of migrated PMNL and IL-8 levels: S r(2)=0.30 (P=ns) vs S+IL-8 r(2)=0.89 (P=0.0002)]. CONCLUSION: Topical anti-IL-8 treatment after lung injury increases IL-8 production, PMNL migration, and worsens lung function in our piglet lavage model. This effect is in contrast to current literature using pre-lung injury treatment protocols. Our data do not support anti-IL-8 treatment in young infants with ARDS.
OBJECTIVE: Acute respiratory distress syndrome (ARDS) in young infants is linked with a pulmonary inflammatory response part of which are increased interleukin-8 (IL-8) levels and migration of polymorphonuclear leukocytes (PMNL) into lung tissue. A topical application of an antibody against IL-8 might therefore decrease PMNL migration and improve lung function. DESIGN: Randomized, controlled, prospective animal study. SETTING: Research laboratory of a university children's hospital. SUBJECTS AND INTERVENTIONS: Anesthetized, mechanically ventilated newborn piglets (n=22) underwent repeated airway lavage to remove surfactant and to induce lung inflammation. Piglets then received either surfactant alone (S, n=8), or a topical antibody against IL-8 admixed to surfactant (S+IL-8, n=8), or an air bolus injection (control, n=6). MEASUREMENTS AND RESULTS: After 6 h of mechanical ventilation following intervention, oxygenation [S 169+/-51 (SD) vs S+IL-8 139+/-61 mmHg] and lung function (compliance: S 1.3+/-0.4 vs S+IL-8 0.9+/-0.4 ml/cmH(2)O/kg; extra-vascular lung-water: S 27+/-9 vs S+IL-8 52+/-28 ml/kg) were worse in the S+IL-8 group because reactive IL-8 production [S 810 (median, range 447-2323] vs S+IL-8 3485 (628-16180) pg/ml; P<0.05) with facilitated migration of PMNL into lung tissue occurred. Moreover, antibody application caused augmented chemotactic potency of IL-8 [linear regression of migrated PMNL and IL-8 levels: S r(2)=0.30 (P=ns) vs S+IL-8 r(2)=0.89 (P=0.0002)]. CONCLUSION: Topical anti-IL-8 treatment after lung injury increases IL-8 production, PMNL migration, and worsens lung function in our piglet lavage model. This effect is in contrast to current literature using pre-lung injury treatment protocols. Our data do not support anti-IL-8 treatment in young infants with ARDS.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Robert P Baughman; Rogene F Henderson; Jeffrey Whitsett; Karen L Gunther; Deborah A Keeton; James J Waide; David S Zaccardelli; Edward N Pattishall; Mitchell C Rashkin Journal: Respiration Date: 2002 Impact factor: 3.580
Authors: J K Shute; B Vrugt; I J Lindley; S T Holgate; A Bron; R Aalbers; R Djukanović Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405
Authors: A Kurdowska; E J Miller; J M Noble; R P Baughman; M A Matthay; W G Brelsford; A B Cohen Journal: J Immunol Date: 1996-09-15 Impact factor: 5.422
Authors: S Chollet-Martin; B Jourdain; C Gibert; C Elbim; J Chastre; M A Gougerot-Pocidalo Journal: Am J Respir Crit Care Med Date: 1996-09 Impact factor: 21.405
Authors: Katharina von der Hardt; Michael Andreas Kandler; Ludger Fink; Ellen Schoof; Jörg Dötsch; Olga Brandenstein; Rainer Maria Bohle; Wolfgang Rascher Journal: Pediatr Res Date: 2003-12-08 Impact factor: 3.756
Authors: M W Rolfe; S L Kunkel; T J Standiford; S W Chensue; R M Allen; H L Evanoff; S H Phan; R M Strieter Journal: Am J Respir Cell Mol Biol Date: 1991-11 Impact factor: 6.914
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker Journal: Intensive Care Med Date: 2006-02-18 Impact factor: 17.440